Eisai to Present New LEQEMBI® Phase 3 and Subcutaneous Formulation Data at CTAD 2023
Eisai
Pharmaceutical Product R&D and Manufacturer
Latest Research Progress on LEQEMBI Subcutaneous Injection Formulation
ShanghaiOctober 17, 2023PR Newswire -- Eisai Co., Ltd. announced that it will present its Alzheimer's disease (AD) treatment drug LEQEMBI at the 16th Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting.®(Lecanemab-irmb) New data from the Phase III Clarity AD study of 100 mg/mL and the ongoing development of a subcutaneous formulation will be presented at the conference to be held from October 24 to 27, 2023, in Boston, Massachusetts, USA. In addition to presenting data on Eisai's LEQEMBI, the conference will also feature Phase I data on E2511 (an investigational tropomyosin receptor kinase A (TrkA) positive allosteric modulator (PAM)) and other research from the company’s Alzheimer’s disease (AD) pipeline. At this conference, Eisai will present data and research findings through five oral presentations and ten poster presentations. BioArctic will give an oral presentation on lecanemab.
Latest Symposium 4 - Lecanemab for the Treatment of Early Alzheimer's Disease: Long-term Efficacy, Predictive Biomarkers, and Novel Subcutaneous Administration
Michael Irizarry, MD, Senior Vice President of Neurology Clinical Research and Deputy Chief Clinical Officer of the Clinical Evidence Generation Department at Eisai, stated, "Alzheimer's disease is a progressive and stubborn illness that requires early diagnosis and continuous treatment. LEQEMBI can remove highly toxic fibrils, thereby supporting neuronal function in Alzheimer's disease, as these highly toxic fibrils continue to cause neuronal damage and death even after plaques are cleared. We look forward to sharing new LEQEMBI low-tau subgroup data and subcutaneous injection data at CTAD 2023."
Other major oral presentations included
Eisai Lecture List:
This press release discusses the investigational use of a drug in development and does not convey conclusions about efficacy or safety, nor does it guarantee that any investigational drug will successfully complete clinical development or receive approval from pharmaceutical regulatory authorities.